Arvin BioHealth (ABH) is a knowledge-based company established in 2016 as a subsidiary of Arvin Pazhoohan Noor (APN) Holding, through the initiative of Dr. Hassan Morovati Khamsi, a faculty member of the Razi Vaccine and Serum Research Institute. ABH focuses on the design, development, manufacture, and export of in-vitro diagnostic (IVD) products, leveraging the expertise of academic researchers, research centers, specialists, and experienced professionals.
   Its portfolio includes human and veterinary rapid diagnostic tests, ELISA, biochemistry and coagulation kits, and diagnostic reagents. ABH is committed to advancing health-oriented technologies, localizing advanced biomedical technologies, and delivering accurate, reliable, user-friendly, and cost-effective diagnostic solutions in compliance with international standards. Supported by modern infrastructure, advanced equipment, cleanroom facilities, qualified specialists, and an ISO 13485:2016-compliant quality management system, ABH serves hospitals, clinical laboratories, medical diagnostic centers, veterinary clinics, and other healthcare institutions.

Design, Development, Manufacture, Assembly, Packaging, Distribution, Marketing, Sale, Installation, Commissioning, Technical Support, and After-Sales Services of In Vitro Diagnostic (IVD) Medical Devices, including Rapid Diagnostic Tests for Fertility, Drugs of Abuse, Infectious Diseases, Tumor Markers, Cardiac Markers, and other related diagnostic applications; Clinical Chemistry Reagents, Calibrators, Controls, and related consumables for Lipid Profile, Glucose Metabolism, Hepatic Function, Renal Function, Cardiac Markers, Coagulation, Special Proteins, Electrolytes, and other Clinical Chemistry Applications; Hematology Analyzers; Coagulation and Hemostasis Analyzers; Chemiluminescence Immunoassay (CLIA) Analyzers; Enzyme-Linked Immunosorbent Assay (ELISA) Diagnostic Kits; and their related diagnostic kits, reagents, calibrators, controls, consumables, accessories, and services.